Ethinylestradiol

Chemical name

(17 альфа)-19-Норпрегна-1,3,5( 10)-триен-20-ин-3,17-диол

Gross

C20-H24-O2

Characteristics

White or kremovato-bely melkochristalliceski powder. Virtually nerastvorim in water, soluble in spirtah and vegetable oils.

Of drugs

The drugs act-mode, anabolicescoe, gipolipidemicescoe. Interfaces with specialized receptors estrogenovmi in kletkah-misheniah. Quickly absorbed by the mucous membranes and skin. Treated gepatoenteralna recycling attendant effects of a "through the liver, which is oxidized to produce and 2-on-etinilestradiola 2-метоксиэтинилэстрад иола and the subsequent glukuronidirovaniu and sulfirovaniu. Metabolites inactive is derived from the urine and jelchew. Depending on the physiological (pregnancy, some phases овариально-менструал��ного cycle, age and other conditions) bring speed varies greatly. The uterine tubes, uterus cervix, vagina, external genitalia, placing alongside mammary glands increases proliferatiou cancer. Increases sensitivity muscles uterus and tubes to their exciting motoriku substances. Assists гипохолестеринемичес кое act increases the blood beta-lipoproteidov, sensitivity to insulino improves glucose utilization. In high doses delaying water and sodium in the body, slowing eritropoez. In high doses, reduces, and in the small-activates the secretion of pituitary opened. Men oppressing spermatogenez (in aickah can develop atroficskie changes), and suppresses the secretion androgenov. And weak Anabolic influence. Under certain conditions, is controlled properties (an integral part of a series of oral contraceptives).

Indications

Some forms of endocrine infertility, severe arthritis pathological, dysfunctional uterine bleeding, androgenzawisimy cancer prostate cancer, some forms of breast cancer.

Contraindications

Bophlebitis, active hepatitis, cirrhosis, arterial hypertension, breast cancer and endometrium, porphyria, and pregnancy.

Side-Effects

Violation calzievogo exchange otechny syndrome, nausea, headache, tromboamboliceski syndrome, arterial hypertension; For men ginekomastia.

Patient interaction

The lower barbiturates (accelerated oxidation).

Dosing and Administration

V / m, the amenoree and oligomenoree - 0,02-0,1 mg / day for 20 days, the on / m impose progesterone for 5 days and 5 mg / sut. In dismenoree treatment beginning with the 4-5 day menstrual cycle, to 0.01-0.03 mg / day (3 receiving) for a period of 20 days, treatment repeated every 2-3 months. To stop feeding appointed in the first three days after giving birth to 0.02 mg three times daily, then in the next three days, 0.01 mg three times a day, and then on the 0.01 mg / day one for 3 days. When treating ordinary teens on 0,03-0,06 mg / sut. When cancer prostate appointed primary dose of 0.05-0.1 mg three times a day, with a gradual decline to support-0.05 mg / sut. When menopausal syndrome, for 0.05 mg / sut.

Directory → Hormones and their antagonists → Estrogens, gestagena; Their homologues and antagonists → Ethinylestradiol